These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 37198017)

  • 1. The increasing age of respiratory syncytial virus-related hospitalisation during COVID-19 pandemic in Lyon was associated with reduced hospitalisation costs.
    Roy Á; Polazzi S; Ploin D; Gillet Y; Javouhey E; Lina B; ; Myard-Dury AF; Couray-Targe S; Duclos A; Casalegno JS
    Vaccine; 2023 Jun; 41(25):3796-3800. PubMed ID: 37198017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005-2017.
    Kim D; Saleem M; Paes B; Mitchell I; Lanctôt KL
    Clin Infect Dis; 2019 Aug; 69(6):980-986. PubMed ID: 30517603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020.
    Packnett ER; Winer IH; Larkin H; Oladapo A; Gonzales T; Wojdyla M; Goldstein M; Smith VC
    Hum Vaccin Immunother; 2022 Nov; 18(6):2140533. PubMed ID: 36412253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.
    Kong AM; Krilov LR; Fergie J; Goldstein M; Diakun D; Wade SW; Pavilack M; McLaurin KK
    Am J Perinatol; 2018 Jan; 35(2):192-200. PubMed ID: 28881376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
    Anderson EJ; DeVincenzo JP; Simões EAF; Krilov LR; Forbes ML; Pannaraj PS; Espinosa CM; Welliver RC; Wolkoff LI; Yogev R; Checchia PA; Domachowske JB; Halasa N; McBride SJ; Kumar VR; McLaurin KK; Rizzo CP; Ambrose CS
    Am J Perinatol; 2020 Mar; 37(4):421-429. PubMed ID: 30991438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study.
    Ares-Gómez S; Mallah N; Santiago-Pérez MI; Pardo-Seco J; Pérez-Martínez O; Otero-Barrós MT; Suárez-Gaiche N; Kramer R; Jin J; Platero-Alonso L; Alvárez-Gil RM; Ces-Ozores OM; Nartallo-Penas V; Mirás-Carballal S; Piñeiro-Sotelo M; Malvar-Pintos A; González-Pérez JM; Rodríguez-Tenreiro-Sánchez C; Rivero-Calle I; Salas A; Durán-Parrondo C; Martinón-Torres F;
    Lancet Infect Dis; 2024 Aug; 24(8):817-828. PubMed ID: 38701823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in chronologic age and infant respiratory syncytial virus hospitalization: an 8-year cohort study.
    Fryzek JP; Martone WJ; Groothuis JR
    Adv Ther; 2011 Mar; 28(3):195-201. PubMed ID: 21327753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29-34 wGA) infants without outpatient palivizumab administration.
    Packnett ER; Winer IH; Oladapo A; Wojdyla M
    Hum Vaccin Immunother; 2023 Aug; 19(2):2252289. PubMed ID: 37828711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Respiratory syncytial virus (RSV) infection in children with medical complexity.
    Lim A; Butt ML; Dix J; Elliott L; Paes B
    Eur J Clin Microbiol Infect Dis; 2019 Jan; 38(1):171-176. PubMed ID: 30374685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restricted Palivizumab Recommendations and the Impact on RSV Hospitalizations among Infants Born at > 29 Weeks of Gestational Age: An Italian Multicenter Study.
    Priante E; Tavella E; Girardi E; Militello MA; Mardegan V; Maule MM; Dall'Agnola A; Baraldi E; Manzoni P
    Am J Perinatol; 2019 Jul; 36(S 02):S77-S82. PubMed ID: 31238365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in the global hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a systematic analysis.
    Cong B; Koç U; Bandeira T; Bassat Q; Bont L; Chakhunashvili G; Cohen C; Desnoyers C; Hammitt LL; Heikkinen T; Huang QS; Markić J; Mira-Iglesias A; Moyes J; Nokes DJ; Ploin D; ; Seo E; Singleton R; Wolter N; Fu Yung C; Zar HJ; Feikin DR; Sparrow EG; ; Nair H; Li Y;
    Lancet Infect Dis; 2024 Apr; 24(4):361-374. PubMed ID: 38141633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the Rate, Severity, and Cost of Respiratory Syncytial Virus Hospitalizations among Preterm Infants.
    Krilov LR; Fergie J; Goldstein M; Brannman L
    Am J Perinatol; 2020 Jan; 37(2):174-183. PubMed ID: 31430818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Respiratory Syncytial Virus and All-Cause Bronchiolitis Hospitalizations Among Preterm Infants Using the Pediatric Health Information System (PHIS).
    Fergie J; Suh M; Jiang X; Fryzek JP; Gonzales T
    J Infect Dis; 2022 Apr; 225(7):1197-1204. PubMed ID: 32691037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus.
    Makari D; Checchia PA; Devincenzo J
    Hum Vaccin Immunother; 2014; 10(3):607-14. PubMed ID: 24316863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study.
    Manzoni P; Paes B; Lanctôt KL; Dall'Agnola A; Mitchell I; Calabrese S; Maule M; Girardi E; Harimoto T; Li A
    Pediatr Infect Dis J; 2017 Jan; 36(1):2-8. PubMed ID: 27649365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical burden of severe respiratory syncytial virus infection during the first 2 years of life in children born between 2000 and 2011 in Scotland.
    Thwaites R; Buchan S; Fullarton J; Morris C; Grubb E; Rodgers-Gray B; Coutts J
    Eur J Pediatr; 2020 May; 179(5):791-799. PubMed ID: 31912234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017.
    Fergie J; Goldstein M; Krilov LR; Wade SW; Kong AM; Brannman L
    Hum Vaccin Immunother; 2021 May; 17(5):1536-1545. PubMed ID: 33090914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Studies of Respiratory Syncytial Virus Hospitalizations among Moderate/Late Preterm Infants Exposed to Passive Immunoprophylaxis with Palivizumab.
    Manzoni P; Baraldi E; Luna MS; Tzialla C
    Am J Perinatol; 2022 Dec; 39(S 01):S7-S13. PubMed ID: 36307092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory syncytial virus prophylaxis in infants with congenital airway anomalies compared to standard indications and complex medical disorders.
    Paes B; Kim D; Saleem M; Wong S; Mitchell I; Lanctot KL;
    Eur J Pediatr; 2019 Mar; 178(3):377-385. PubMed ID: 30610419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seasonal peaks and risk factors of respiratory syncytial virus infections related hospitalization of preterm infants in Taiwan.
    Chi H; Chung CH; Lin YJ; Lin CH
    PLoS One; 2018; 13(5):e0197410. PubMed ID: 29746578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.